Frank Morgan’s Insider Option Buy Signals Confidence in Modular Medical’s Growth

Insider Confidence Amid a Volatile Market

On June 30, 2026, director Frank Morgan C. exercised a sizable block of options in Modular Medical Inc., adding 312 shares to his portfolio after a combined purchase of 312 shares through two separate option grants. The transaction, executed at a price of $4.61 per share, aligns with the company’s Outside Director Compensation Plan, which fully vests and grants exercisability on the grant date. Although the trade’s dollar value is modest—just over $1,400—its timing is telling. The stock had just closed at $4.50, marking a 9.88 % weekly rally but a sharp 11.01 % monthly decline, and the company’s market cap sits at $26.4 million.

Implications for Investors

The purchase is a subtle signal that an insider remains optimistic about Modular’s pivot from development to commercialization, especially after the FDA clearance of its Pivot tubeless insulin patch pump in April. The company’s recent launch has sparked modest buzz (57.94 %) but no strong market sentiment shift, reflecting a cautious yet hopeful outlook. Investors should note that the price‑earnings ratio is negative, a typical feature of a growth‑stage biotech, and that the stock’s 52‑week high ($30) has been eclipsed by a low of $3.13, suggesting volatility remains high. In this context, an insider purchase—despite its small size—can reinforce confidence in the company’s strategic trajectory and may act as a catalyst for short‑term price momentum.

Frank Morgan C.: A Pattern of Support

Frank Morgan’s insider history shows a consistent pattern of option purchases, with four large buys in September 2025 (2,875 and 9,375 shares) and two in March 2025 (1,875 and 9,375 shares). In June 2026, he added 62 and 250 shares, mirroring the earlier pattern of incremental stake‑building. Unlike other insiders who have taken large positions in common stock—such as Steven G. Felshere’s 60,000‑share purchase in December 2025—Morgan’s activity is confined to options, indicating a long‑term horizon and a willingness to ride out price swings before committing to a cash purchase. This disciplined approach suggests that Morgan views the company’s technology as a durable, albeit volatile, investment.

Broader Insider Landscape

The company’s insider activity is largely concentrated in option purchases, with notable buys by COO Kevin Schmid and others such as Paul DiPerna and Ellen O’Connor. The pattern reflects a cohort of executives who are comfortable leveraging the Outside Director Compensation Plan to build equity over time. The recent concentration of option purchases in the first quarter of 2026 signals that insiders are preparing for the next phase of product rollout and market expansion, potentially aligning with the company’s partnership with a major medical‑device manufacturer to scale production.

Investor Takeaway

For investors watching a stock that has recently shifted from R&D to market, the latest insider purchase by Frank Morgan is a subtle endorsement of the company’s growth prospects. While the trade’s size is small relative to the market cap, it confirms insider confidence amid a volatile market and may encourage other shareholders to reassess the potential upside of Modular’s pivot technology. Keeping an eye on subsequent insider transactions—particularly any conversion of options into common stock—will provide a clearer view of the company’s long‑term capital structure and commitment to its commercial strategy.